Summarized by Masters of Longevity from Lifespan.io.
Policy-focused article about regulators elevating aging and longevity as an agency priority and outlining potential approval pathways and research needs.
Key Takeaways
- The FDA will add aging and longevity to its Focus Areas of Regulatory Science, signaling organizational priority and planned guidance development.
- Regulators described two approval pathways for gerotherapeutics: demonstrating benefits across multiple age-related conditions or showing slowed decline in intrinsic physical and mental capacities.
- Experts urged pre-competitive collaboration to standardize and validate biomarkers, enabling shorter trials and pooled evidence for regulatory acceptance.
